Knochenmetastasen – Pathophysiologie, Diagnostik und Therapie (Teil 1)

Zusammenfassung

Maligne Neoplasien sind in Deutschland nach den kardiovaskulären Erkrankungen weiterhin die zweithäufigste Todesursache. Obwohl sich die 5-Jahres-Überlebensraten der meisten malignen Tumoren in Deutschland in den letzten 30 Jahren signifikant verbessert haben, gilt eine ossäre Metastasierung mit wenigen Ausnahmen weiterhin als Zeichen der Inkurabilität. Neben den seltenen primären Knochentumoren macht die Behandlung von ossären Absiedlungen von Karzinomen einen großen Teil der tumororthopädischen Tätigkeit aus, die zudem eine enge interdisziplinäre Abstimmung mit der inneren Medizin, Radiologie und der entsprechenden Fachdisziplin der zugrunde liegenden Entität erfordert. Durch die Fortschritte in der onkologischen Therapie des Primärtumors wird z. T. ein sehr langes Überleben erreicht, sodass das Management von SRE („skeletal related events“) auch bei palliativen Situationen an Relevanz gewinnt. Die vorliegende Übersichtsarbeit geht in ihrem 1. Teil auf der Grundlage einer aktuellen selektiven Literaturübersicht auf die zuvor erwähnten pathophysiologischen Zusammenhänge der ossären Metastasierung ein und stellt im Folgenden einzelne Diagnostika und deren Relevanz dar.

Abstract

In Germany and other European countries, cancer is the second most common cause of death after cardiovascular disease. Although 5-year survival rates for several types of cancer have significantly improved over the last 30 years, metastasis to the bone almost always leads to incurable disease. Aside from the rare primary bone tumours, the treatment of bone metastases now accounts for a major part of tumour orthopaedic workload and requires close interdisciplinary coordination between specialists in oncology, radiology and the discipline of the primary tumour entity. Due to improvements in oncological treatment regimes, long survival times can be achieved. Therefore, the management of so-called “SRE” (skeletal-related events) has gained importance, even in palliative situations. On the basis of a selective literature review, the following article points out the underlying pathophysiological processes of bone metastases and outlines different diagnostic approaches and their relevance in the current clinical setting.

Schlüsselwörter

Knochenmetastasen - Tumororthopädie - Metastasierung - pathologische Fraktur

Key words

bone metastases - tumour orthopedics - metastases - pathological fracture

• Literatur

• 1 Becker N, Holzmeier S. Zeitlicher Trend der Fallzahlen und standardisierte Mortalitätsraten. Heidelberg: Deutsches Krebsforschungszentrum; 2016
• 2 (Hrsg.) Robert Koch-Institut. Krebs in Deutschland 2005/2006 – Häufigkeiten und Trends. 7. Ausgabe. Berlin: Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.; 2010
• 3 Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664
• 4 DeVita VT, Lawrence TS, Rosenberg SA. et al. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams;& Wilkins; 2001
• 5 Haberland J, Wolf U. Trendanalysen zur Inzidenz und Mortalität an Krebs in Deutschland seit 1970. Berlin: Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V.; 2015
• 6 Lin PP, Mirza AN, Lewis VO. et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89: 1794-1801
• 7 Utzschneider S, Weber P, Fottner A. et al. [Prognosis-adapted surgical management of bone metastases]. Orthopade 2009; 38: 308 310–312, 314–315
• 8 Agarwal MG, Nayak P. Management of skeletal metastases: an orthopaedic surgeonʼs guide. Indian J Orthop 2015; 49: 83-100
• 9 Pereira J, Body JJ, Gunther O. et al. Cost of skeletal complications from bone metastases in six European countries. J Med Econ 2016; 19: 611-618
• 10 Guise TA, Mohammad KS, Clines G. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s-6216s
• 11 Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med 2006; 6: 145-149
• 12 Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000; 5: 75-81
• 13 Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-425
• 14 Stenzl A, Fehm T, Hofbauer LC. et al. Knochenmetastasen – Pathophysiologie, Diagnostik und Therapie. Heidelberg: Springer Medizin; 2014
• 15 Aad G, Abbott B, Abdallah J. et al. Search for scalar diphoton resonances in the mass range 65–600 GeV with the ATLAS detector in pp collision data at radicals=8 TeV. Phys Rev Lett 2014; 113: 171801
• 16 Hofbauer LC, Rachner T, Singh SK. Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res 2008; 10: 101
• 17 Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 2008; 8: 377-386
• 18 Vignery A. Macrophage fusion: are somatic and cancer cells possible partners?. Trends Cell Biol 2005; 15: 188-193
• 19 Krzeszinski JY, Wan Y. New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci 2015; 36: 360-373
• 20 Weidle UH, Birzele F, Kollmorgen G. et al. Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics 2016; 13: 1-12
• 21 Heindel W, Gübitz R, Vieth V. et al. The diagnostic imaging of bone metastases. Dtsch Arztebl Int 2014; 111: 741-747
• 22 OʼSullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol 2015; 7: 202-211
• 23 Luzzi KJ, MacDonald IC, Schmidt EE. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-873
• 24 Aft R, Naughton M, Trinkaus K. et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428
• 25 Coleman RE, Guise TA, Lipton A. et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008; 14: 6387-6395
• 26 Choi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control 2012; 19: 102-112
• 27 Layer G. Skelettmetastasen. Berlin, Heidelberg: Springer; 2005
• 28 Hamaoka T, Madewell JE, Podoloff DA. et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22: 2942-2953
• 29 Rajarubendra N, Bolton D, Lawrentschuk N. Diagnosis of bone metastases in urological malignancies – an update. Urology 2010; 76: 782-790
• 30 Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging 2011; 55: 374-410
• 31 Horger M, Claussen CD, Bross-Bach U. et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005; 54: 289-297
• 32 Vassiliou V, Andreopoulos D, Frangos S. et al. Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol (R Coll Radiol) 2011; 23: 632-645
• 33 Vanel D, Bittoun J, Tardivon A. MRI of bone metastases. Eur Radiol 1998; 8: 1345-1351
• 34 Nilsen LB, Fangberget A, Geier OM. et al. Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis. J Magn Reson Imaging 2014; 40: 1382-1391
• 35 Herneth AM, Naude J, Philipp M. et al. [The value of diffusion-weighted MRT in assessing the bone marrow changes in vertebral metastases]. Radiologe 2000; 40: 731-736
• 36 Li C, Liu ZS, Du XM. et al. Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases. Chin Med Sci J 2009; 24: 112-116
• 37 Heusner TA, Kuemmel S, Koeninger A. et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010; 37: 1077-1086
• 38 Smith-Bindman R. Is computed tomography safe?. N Engl J Med 2010; 363: 1-4
• 39 Padhani AR, Makris A, Gall P. et al. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging 2014; 39: 1049-1078
• 40 Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005; 46: 1356-1367
• 41 Coleman RE, Mashiter G, Whitaker KB. et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354-1359
• 42 Gnanasegaran G, Cook G, Adamson K. et al. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT/CT. Semin Nucl Med 2009; 39: 380-395
• 43 Cuccurullo V, Cascini GL, Tamburrini O. et al. Bone metastases radiopharmaceuticals: an overview. Curr Radiopharm 2013; 6: 41-47
• 44 Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel) 2014; 6: 1821-1889
• 45 Bauerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol 2009; 19: 2495-2507
• 46 Plathow C, Walz M, Lichy MP. et al. [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]. Radiologe 2008; 48: 384-396
• 47 Ulrich U, Rhiem K, Schmolling J. et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 2001; 264: 186-190
• 48 Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010; 12: 685-696
• 49 Tanko LB, Karsdal MA, Christiansen C. et al. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?. Cancer Metastasis Rev 2006; 25: 659-668
• 50 Ebert W, Muley T, Herb KP. et al. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004; 24: 3193-3201
• 51 Jung K, Lein M, Ringsdorf M. et al. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 2006; 176: 1326-1331
• 52 Pramesh CS, Deshpande MS, Pardiwala DN. et al. Core needle biopsy for bone tumours. Eur J Surg Oncol 2001; 27: 668-671
• 53 Ball AB, Fisher C, Pittam M. et al. Diagnosis of soft tissue tumours by Tru-Cut biopsy. Br J Surg 1990; 77: 756-758
• 54 Monfardini L, Preda L, Aurilio G. et al. CT-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures. Radiol Med 2014; 119: 852-860
• 55 Vandecandelaere M, Flipo RM, Cortet B. et al. Bone metastases revealing primary tumors. Comparison of two series separated by 30 years. Joint Bone Spine 2004; 71: 224-229
• 56 Xu DL, Zhang XT, Wang GH. et al. [Clinical features of pathologically confirmed metastatic bone tumors – a report of 390 cases]. Ai Zheng 2005; 24: 1404-1407
• 57 Plot L, Dovrish Z, Hadari R. et al. [Cancer of unknown primary site origin–advances in diagnosis and therapy]. Harefuah 2008; 147: 294-298 375, 376
• 58 Piccioli A, Maccauro G, Spinelli MS. et al. Bone metastases of unknown origin: epidemiology and principles of management. J Orthop Traumatol 2015; 16: 81-86
• 59 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247